| Literature DB >> 32021101 |
Yunfei Wang1,2, Zhengrong Li2, Boxue Liu1,2, Rumeng Wu1,2, Haifeng Gong2, Zhanhai Su2, Shoude Zhang1,2.
Abstract
PURPOSE: Isoborneol has been used in the treatment of cardiovascular disease for several years in China. However, the mechanism is still unclear. The aim of this study was to identify the novel mechanism of isoborneol for its application in atherosclerotic disease.Entities:
Keywords: atherosclerosis; connectivity map; ikarugamycin; isoborneol; macrophage; ox-LDL
Mesh:
Substances:
Year: 2020 PMID: 32021101 PMCID: PMC6970257 DOI: 10.2147/DDDT.S233013
Source DB: PubMed Journal: Drug Des Devel Ther ISSN: 1177-8881 Impact factor: 4.162
Figure 1Identification of isoborneol as sharing a similar gene expression profile with ikarugamycin. (A) Summary flow chart showing the identification of isoborneol as an inhibitor for the uptake of ox-LDL by RAW 264.7 cells. (B) Heat map representing the isoborneol-regulated genes (20 most up-regulated, red; 20 most down-regulated, green) obtained from MCF-7 cells treated with control or isoborneol. (10 μM, 12 h). (C) Distribution of the absolute enrichment scores of the individual compounds in the CMAP database obtained using the isoborneol gene expression signature. (D) Heat maps generated from the CMAP database representing the isoborneol-regulated genes (40 most up-regulated, red; 40 most down-regulated, green) and the corresponding changes in the same genes induced by ikarugamycin.
Figure 2Isoborneol attenuates ox-LDL-induced lipid accumulation in macrophage foam cells. (A) RAW 264.7 macrophages were pretreated with isoborneol for 24 hrs, and then stimulated with 50 µg/mL ox-LDL for 24 hrs. After incubation, the extent of lipid loading was assessed by Oil Red O staining. The cells were observed with bright-field microscopy. The magnification of each panel is ×400. (B) The lipid content in RAW 264.7 macrophages after treating with or without Isoborneol. Values are the means ± SD from at least three separate experiments. *P<0.05 vs the control was treated with vehicle (zero ox-LDL and zero isoborneol).
Figure 3Isoborneol inhibited the uptake of ox-LDL by macrophages. (A) RAW 264.7 macrophages were cultured in isoborneol at different concentrations for 24 hrs, then loaded with 20 μg/mL Dil-ox-LDL for an additional 4 hrs. The magnification of each panel is ×400. (B) Fluorescence intensity of each group. Values are the means ± SD from at least three separate experiments. *P<0.05 vs the control was treated with vehicle (zero isoborneol).
Enriched KEGG Pathways
| Pathway | Description | Count in Gene Set | False Discovery Rate |
|---|---|---|---|
| hsa05200 | Pathways in cancer | 26 of 515 | 0.0136 |
| hsa05203 | Viral carcinogenesis | 13 of 183 | 0.0203 |
| hsa04810 | Regulation of actin cytoskeleton | 14 of 205 | 0.0203 |
| hsa04015 | Rap1 signaling pathway | 14 of 203 | 0.0203 |
| hsa04010 | MAPK signaling pathway | 17 of 293 | 0.0203 |
| hsa04540 | Gap junction | 8 of 87 | 0.0314 |
| hsa05032 | Morphine addiction | 8 of 91 | 0.0354 |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 8 of 92 | 0.0354 |
| hsa04072 | Phospholipase D signaling pathway | 10 of 145 | 0.0385 |